The dispute centers on Monsanto’s popular line of Roundup herbicide products, whose main active ingredient is glyphosate.

The U.S. Supreme Court’s ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. could either discourage the development of generic drugs under a skinny label or make innovators think long and ...

The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...

Though Botox is not yet approved by the Food and Drug Administration (FDA) for trigeminal neuralgia (TN), doctors sometimes use Botox injections “off-label” as a treatment option for TN. Botox is ...

The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...

Researchers at Baylor College of Medicine and collaborating institutions developed a method that reveals the cellular makeup ...

Supreme Court justices on Wednesday will hear arguments in a patent case that could change the way generic drug companies ...